Nektar Therapeutics NKTR announced that the phase IIb REZOLVE-AD study evaluating its lead pipeline candidate, ...

Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin ...

Gossamer Bio Inc. (NASDAQ:GOSS) is one of the best biotech stocks to invest in now. On June 16, Gossamer Bio announced the ...

The results indicated that subjects who switched from alglucosidase alfa to cipa+mig generally achieved improvements or ...

The S&P 500 (^GSPC) flirted with all-time highs but ended the day nearly flat, just shy of its record level. Nvidia shares ...

Shares of Nektar Therapeutics soared after the company said it would release topline data from a study of its atopic dermatitis treatment rezpegaldesleukin. The stock was up 31% at $12.49 in Monday's ...

Shares of BP rose Wednesday, lifted by a report that Shell was in talks to acquire it in what would mark a huge deal for the ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

Hitting the primary endpoint on Compass Pathways plc’s Comp005 study of synthetic psilocybin, which the company billed as the first classic psychedelic to report phase III efficacy data, produced only ...

Last year’s strong stock-market returns may drive more foundation giving in 2025, and fundraisers should focus on DAF donors.

Compass Pathways plc downgraded to Hold after mixed trial results. Explore upcoming catalysts in depression treatment and ...